mBio
(Jun 2021)
An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
Yan Guo,
Wenhui He,
Huihui Mou,
Lizhou Zhang,
Jing Chang,
Shoujiao Peng,
Amrita Ojha,
Rubens Tavora,
Mark S. Parcells,
Guangxiang Luo,
Wenhui Li,
Guocai Zhong,
Hyeryun Choe,
Michael Farzan,
Brian D. Quinlan
Affiliations
Yan Guo
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Wenhui He
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Huihui Mou
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Lizhou Zhang
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Jing Chang
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Shoujiao Peng
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Amrita Ojha
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Rubens Tavora
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Mark S. Parcells
Department of Animal and Food Sciences, University of Delaware, Newark, Delaware, USA
Guangxiang Luo
ORCiD Department of Microbiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
Wenhui Li
National Institute of Biological Sciences, Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China
Guocai Zhong
Scripps Research SZBL Chemical Biology Institute, Shenzhen Bay Laboratory, Shenzhen, China
Hyeryun Choe
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Michael Farzan
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
Brian D. Quinlan
Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, Florida, USA
DOI
https://doi.org/10.1128/mBio.00930-21
Journal volume & issue
Vol. 12,
no. 3
Abstract
Read online
All available vaccines for coronavirus disease 2019 (COVID-19) express or deliver the full-length SARS-CoV-2 spike (S) protein. We show that this antigen is not optimal, consistent with observations that the vast majority of the neutralizing response to the virus is focused on the S-protein receptor-binding domain (RBD).
WeChat QR code
Close
